Dianthus Therapeutics, Inc. Price & Performance (DNTH)

Juvena Therapeutics is set to begin first-in-human dosing of its fusion protein candidate JUV-161 next month, after receiving A-track approval and completing its IND package. The therapy targets muscle-wasting diseases, including myotonic dystrophy type one, and represents a significant milestone in Juvena’s pipeline for regenerative medicine.12

Latigo Biotherapeutics has raised $150 million in Series B financing, led by Blue Owl Capital, to advance clinical development of its non-opioid pain treatment, LTG-001. The candidate recently received FDA fast track designation following positive Phase I data, highlighting growing investor confidence in alternatives to opioid pain management.34

Magenta Therapeutics’ stock price fluctuated between $17.16 and $19.09 today, reflecting ongoing volatility and a broader downward trend over the past year. Despite a 131% five-year return, the company’s shares are down over 30% year-on-year, with analysts maintaining a neutral outlook as the market digests recent performance.56